Supplementary Material. Atezolizumab with bevacizumab, PTX and CBDCA was effective for patients with SMARCA4-deficient thoracic sarcoma
收藏数据链接：
官方服务：
资源简介：
Supplementary Table 1 – Mutation profile of patients in Case 1, Case 2, and Case 3
提供机构：
Taylor & Francis创建时间：
2021-05-25
